23.03.2010 • NewsLanxessunder constructionchlorotoluenes

Expansion of Basic Chemicals Facilities at Lanxess on Schedule

In the coming weeks, the capacity expansion program for chlorotoluenes, cresols and their derivatives that Lanxess announced in late October 2008 will reach completion, the company has reported. The specialty chemicals company said it will then have up to 60% higher capacities for these important basic chemicals for the global market. In total, the Basic Chemicals business unit (BAC) will have invested around €35 million in this network of facilities in Leverkusen.

"Despite the economic downturn, we've continued to move forward with the project because a major percentage of this expansion in volume is supported by contractual agreements," says Dr. Hans-Georg Schmitt, head of BAC.

The expansion program, which is nearing completion, also includes plans to increase the manufacture of menthol. In collaboration with Symrise, a project has been launched to significantly extend menthol capacities. Dr. Norbert Richter, senior vice president of the Aroma Molecules Business Unit of Symrise, a fragrance and flavoring manufacturer, welcomes the availability of higher capacities at Lanxess for manufacturing this precursor: "Symrise produces menthol using raw materials from Lanxess. Reliable supply is of critical importance to us, because menthol is a key component in many aromas for the oral hygiene and chewing gum segments. It further is used in a variety of pharmaceutical products."

Company

Logo:

LANXESS Deutschland GmbH

Kennedyplatz 1
50569 Köln
Germany

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
24.01.2025 • News

CEFIC Publishes 2024 Facts and Figures Report

CEFIC , the European Chemical Industry Council, has published its 2024 Facts & Figures report, which reinforces the need to take bold and urgent action to secure Europe’s industrial future, not only to implement the Green Deal but also to prevent further de-industrialization in Europe.